Javascript must be enabled to continue!
IDENTIFICATION OF NEW CYCLOOXYGENASE-2 SELECTIVE INHIBITORS VIA VIRTUAL SCREENING AND COMPLEX-BASED PHARMACOPHORE MAPPING
View through CrossRef
Background: New and effective COX-2-targeted medications may cure cancer, inflammation, and other disorders.It’s difficult to produce druggable site inhibitors for target protein inhibition that are strong and selective. Such medications need a more informed structure-based or ligand-based drug discovery technique. MOE was used to create asix-point COX-2 selective inhibitor pharmacophore from 43 compounds. The structure includes three aromatic rings,one hydrophobic group (Hyd), one donor (Don), and three H-bond acceptors. A pharmacophore was used to digitallyfilter the Chembridge database to locate additional structural poses that fulfilled the model’s requirements. We found2090 structurally diverse hits after filtering. Molecular docking was performed on 767 hits after Lipinski’s rule of fivedetermined druggability. Twenty compounds with high active site amino acid residue interactions and diverse scaffoldswere chosen. The first COX-2 isoform-inhibiting medicines were discovered using structure-based pharmacophores.Objectives Using complex-based pharmacophore mapping and virtual screening, this research seeks novel selectiveCOX-2 inhibitors. This involves filtering through a chemical database, defining critical interactions, maximizing hits,and extending drug development for safer and more effective inflammation and pain managemStudy design : Employing Advanced Computational And Pharmacological Approaches StudyDuration and place of study :The study was conducted at Abdul Wali Khan University Mardan from jan2017 to jan 2018Methods: The investigation used a structure-based drug discovery methodology to find novel cyclooxygenase-2 (COX-2)selective inhibitors. The COX-2 crystal structure was used to create a pharmacophore model, which was then used tovirtually search a chemical database. In order to identify potential lead compounds based on interactions with importantCOX-2 residues, binding energies were computed, and molecular docking was used to refine hits.Results: The goal of the project was to use virtual screening and complex-based pharmacophore mapping to findnovel selective COX-2 inhibitors. After the COX-2 crystal structure was used to create a pharmacophore model,2090 hits were discovered in a database. Following the druggability assessment, 767 hits were chosen for moleculardocking. Ultimately, twenty compounds were found to be promising COX-2 inhibitors due to their strong interactionswith COX-2 and variety of scaffolds.Conclusion: This study found 20 possible lead drugs that selectively block cyclooxygenase-2 (COX-2) using complex-based pharmacophore mapping and virtual screening. These substances show a variety of scaffolds and robustinteractions with COX-2, making them attractive candidates for further research and development as anti-inflammatoryand anti-cancer medications with maybe fewer adverse effects.Keywords: Cyclooxygenase-2 (COX-2),Pharmacophore mapping,Virtual screening,Drug discovery
Bacha Khan Medical College
Title: IDENTIFICATION OF NEW CYCLOOXYGENASE-2 SELECTIVE INHIBITORS VIA VIRTUAL SCREENING AND COMPLEX-BASED PHARMACOPHORE MAPPING
Description:
Background: New and effective COX-2-targeted medications may cure cancer, inflammation, and other disorders.
It’s difficult to produce druggable site inhibitors for target protein inhibition that are strong and selective.
Such medications need a more informed structure-based or ligand-based drug discovery technique.
MOE was used to create asix-point COX-2 selective inhibitor pharmacophore from 43 compounds.
The structure includes three aromatic rings,one hydrophobic group (Hyd), one donor (Don), and three H-bond acceptors.
A pharmacophore was used to digitallyfilter the Chembridge database to locate additional structural poses that fulfilled the model’s requirements.
We found2090 structurally diverse hits after filtering.
Molecular docking was performed on 767 hits after Lipinski’s rule of fivedetermined druggability.
Twenty compounds with high active site amino acid residue interactions and diverse scaffoldswere chosen.
The first COX-2 isoform-inhibiting medicines were discovered using structure-based pharmacophores.
Objectives Using complex-based pharmacophore mapping and virtual screening, this research seeks novel selectiveCOX-2 inhibitors.
This involves filtering through a chemical database, defining critical interactions, maximizing hits,and extending drug development for safer and more effective inflammation and pain managemStudy design : Employing Advanced Computational And Pharmacological Approaches StudyDuration and place of study :The study was conducted at Abdul Wali Khan University Mardan from jan2017 to jan 2018Methods: The investigation used a structure-based drug discovery methodology to find novel cyclooxygenase-2 (COX-2)selective inhibitors.
The COX-2 crystal structure was used to create a pharmacophore model, which was then used tovirtually search a chemical database.
In order to identify potential lead compounds based on interactions with importantCOX-2 residues, binding energies were computed, and molecular docking was used to refine hits.
Results: The goal of the project was to use virtual screening and complex-based pharmacophore mapping to findnovel selective COX-2 inhibitors.
After the COX-2 crystal structure was used to create a pharmacophore model,2090 hits were discovered in a database.
Following the druggability assessment, 767 hits were chosen for moleculardocking.
Ultimately, twenty compounds were found to be promising COX-2 inhibitors due to their strong interactionswith COX-2 and variety of scaffolds.
Conclusion: This study found 20 possible lead drugs that selectively block cyclooxygenase-2 (COX-2) using complex-based pharmacophore mapping and virtual screening.
These substances show a variety of scaffolds and robustinteractions with COX-2, making them attractive candidates for further research and development as anti-inflammatoryand anti-cancer medications with maybe fewer adverse effects.
Keywords: Cyclooxygenase-2 (COX-2),Pharmacophore mapping,Virtual screening,Drug discovery.
Related Results
Therapeutic potential of SGLT-2 inhibitors and DDP4 inhibitors in elderly patients with type 2 diabetes mellitus and benign prostatic hyperplasia
Therapeutic potential of SGLT-2 inhibitors and DDP4 inhibitors in elderly patients with type 2 diabetes mellitus and benign prostatic hyperplasia
Background. Benign prostatic hyperplasia (BPH) has recently been linked to diabetes mellitus and insulin resistance. This study aims to explore whether the use of either sodium-glu...
Role of COX-2 in the Enhanced Vasoconstrictor Effect of Arachidonic Acid in the Diabetic Rat Kidney
Role of COX-2 in the Enhanced Vasoconstrictor Effect of Arachidonic Acid in the Diabetic Rat Kidney
In the rat isolated perfused kidney, arachidonic acid elicits cyclooxygenase-dependent vasoconstriction through activation of PGH
2
/TxA
2
...
The feasibility of risk-stratified screening as routine practice in the NHS Breast Screening Programme in England: the PROCAS2 research programme
The feasibility of risk-stratified screening as routine practice in the NHS Breast Screening Programme in England: the PROCAS2 research programme
Background
Screening for breast cancer produces benefits through cancers being detected earlier, thereby reducing premature deaths and the need for more intensi...
Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis
Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis
IntroductionThis meta-analysis aims to evaluate the efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors [PD-(L)1 inhibitors] for muscle-invasive bladder carcinom...
Pharmacophore model guided 3D molecular generation through diffusion model
Pharmacophore model guided 3D molecular generation through diffusion model
Generating molecules that rigorously satisfy three-dimensional (3D) pharmacophore constraints has remained a challenge in de novo drug design, despite rapid progress in molecular g...
Combined Ligand-Based and Structure-Based Virtual Screening Approach for Identification of New Dipeptidyl Peptidase 4 Inhibitors
Combined Ligand-Based and Structure-Based Virtual Screening Approach for Identification of New Dipeptidyl Peptidase 4 Inhibitors
Background:
Dipeptidyl Peptidase 4 (DPP 4) enzyme cleaves an incretin-based glucoregulatory
hormone Glucagon Like Peptide -1 from N-terminal where penultimate amino acid is either ...
Design of potent telomerase inhibitors using ligand-based approaches and molecular dynamics simulations studies
Design of potent telomerase inhibitors using ligand-based approaches and molecular dynamics simulations studies
Abstract
Telomerase is a well-recognised and a promising target for cancer therapy. In this study, we selected ligand-based approaches to design telomerase inhibitors for t...
Determinants of breast and cervical cancer screening uptake among women in Zambia: analysis of the 2024 Zambia demographic and health survey
Determinants of breast and cervical cancer screening uptake among women in Zambia: analysis of the 2024 Zambia demographic and health survey
Abstract
Breast and cervical cancers remain leading causes of cancer-related morbidity and mortality among women globally, particularly in low- and middle-income ...

